May 2011 - FRMC

Volume
8
Issue 5
May 2011

FEATURES

Christin Melton

Minneapolis—In a single-arm, multicenter, observational study of patients in the United States with type 2 diabetes (T2D), twice-daily administration of exenatide was associated with significantly lower glycosylated hemogl | Read More
Citation:

Tori Socha

Organizing care involves the marshalling of personnel and other resources needed to carry out all required patient care activities. | Read More
Citation:

Tori Socha

The Affordable Care Act of 2010 places emphasis on the use of health information technology and its potential to reduce healthcare costs and improve health outcomes.  | Read More
Citation:

Tim Casey

Minneapolis—Approved by the US Food and Drug Administration (FDA) in 1954, warfarin has been the standard of care for decades for many patients with thromboembolic disorders. Still, some physicians are reluctant to prescribe warfarin because of side effects, including the risk of major bleeding. | Read More
Citation:

DEPARTMENTS

Tim Casey

Minneapolis—When the US Food and Drug Administration (FDA) approved interferon beta-1b, a biotechnology product, in 1993, the treatment approach regarding multiple sclerosis (MS) changed, according to Gary M. Owens, MD, president of Gary Owens Associates in Glen Mills, Pennsylvania. | Read More
Citation:

Tori Socha

Minneapolis—In a contemporary issues session at the AMCP meeting titled Specialty Pharmaceuticals Pipeline Update, attendees heard from Aimee Tharaldson, PharmD, senior clinical consultant, emerging therapeutics, at Express Scripts. Dr. Tharaldson began the session by listing the objectives of her presentation: describe key specialty market trends, discuss the current specialty market, and highlight the near-term specialty pipeline. | Read More
Citation:

Tim Casey

The number of products in the pharmaceutical pipeline is less than it was from 2007 through 2009. | Read More
Citation: